| Cathy Michelle Tincher, PA-C | |
|
6007 Us Route 60 E, Suite 203, Barboursville, WV 25504-1042 | |
| (304) 691-8690 | |
| (304) 691-8698 |
| Full Name | Cathy Michelle Tincher |
|---|---|
| Gender | Female |
| Speciality | Physician Assistant |
| Experience | 14 Years |
| Location | 6007 Us Route 60 E, Barboursville, West Virginia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1922300219 | NPI | - | NPPES |
| 01539 | Other | WV | WV BOARD OF MEDICINE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363A00000X | Physician Assistant | 1539 (West Virginia) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Physicians And Surgeons, Inc | 2961315734 | 324 |
News Archive
Despite ongoing public health efforts, E. coli outbreaks continue to infiltrate the food supply, annually causing significant sickness and death throughout the world. But the research community is gaining ground. In a major finding, published today in the scientific journal Nature, researchers from the La Jolla Institute for Allergy & Immunology have discovered a molecule's previously unknown role in fighting off E. coli and other bacterial infections, a discovery that could lead to new ways to protect people from these dangerous microorganisms.
A supplement some people turn to in hopes of losing a few pounds may have some previously unknown, unsavory side effects, suggest two new studies.
A phase I clinical trial showed diffuse, large B-cell lymphomas (DLBCLs) resistant to chemotherapy can be reprogrammed to respond to treatment using the drug azacitidine, according to a study published in Cancer Discovery, a journal of the American Association for Cancer Research.
Today 15 million persons throughout the world suffer from an ictus every year and 5 million are left with chronic disabilities. FIK designed a system for alleviating neuromuscular disability amongst these patients from their homes and by which these can be permanently supervised by the therapist who will be able to carry out a quantitative evaluation of the therapy. To this end, they have brought together new technologies and entertainment and a greater quality of rehabilitation.
OSI Pharmaceuticals and Genentech have announced that OSI completed the submission of a New Drug Application with the U.S. Food and Drug Administration for Tarceva (erlotinib HCl),
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Cathy Michelle Tincher, PA-C 6007 Us Route 60 E, Suite 203, Barboursville, WV 25504-1042 Ph: (304) 691-8690 | Cathy Michelle Tincher, PA-C 6007 Us Route 60 E, Suite 203, Barboursville, WV 25504-1042 Ph: (304) 691-8690 |
News Archive
Despite ongoing public health efforts, E. coli outbreaks continue to infiltrate the food supply, annually causing significant sickness and death throughout the world. But the research community is gaining ground. In a major finding, published today in the scientific journal Nature, researchers from the La Jolla Institute for Allergy & Immunology have discovered a molecule's previously unknown role in fighting off E. coli and other bacterial infections, a discovery that could lead to new ways to protect people from these dangerous microorganisms.
A supplement some people turn to in hopes of losing a few pounds may have some previously unknown, unsavory side effects, suggest two new studies.
A phase I clinical trial showed diffuse, large B-cell lymphomas (DLBCLs) resistant to chemotherapy can be reprogrammed to respond to treatment using the drug azacitidine, according to a study published in Cancer Discovery, a journal of the American Association for Cancer Research.
Today 15 million persons throughout the world suffer from an ictus every year and 5 million are left with chronic disabilities. FIK designed a system for alleviating neuromuscular disability amongst these patients from their homes and by which these can be permanently supervised by the therapist who will be able to carry out a quantitative evaluation of the therapy. To this end, they have brought together new technologies and entertainment and a greater quality of rehabilitation.
OSI Pharmaceuticals and Genentech have announced that OSI completed the submission of a New Drug Application with the U.S. Food and Drug Administration for Tarceva (erlotinib HCl),
› Verified 8 days ago
Rachel Elizabeth Chapman, Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 414 Ledgestone Dr, Barboursville, WV 25504 Phone: 304-561-4698 | |
Amy Beth Cope, PA-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 6171 Childers Road, Barboursville, WV 25504 Phone: 304-733-5380 Fax: 304-733-5796 | |
Mr. Tommy D Dooley Ii, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 6007 U.s. Rt. 60 E. Suite 130, Barboursville, WV 25504 Phone: 304-733-3333 Fax: 304-733-3666 | |
Easton Petitt, Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 996 Fudges Creek Rd, Barboursville, WV 25504 Phone: 304-417-1596 | |
Regina D Grome, PA-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 143 Peyton Street, Barboursville, WV 25504 Phone: 304-697-2035 Fax: 304-523-1485 | |
Melissa Marie Mccoy, Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 5187 Heath Creek Rd, Barboursville, WV 25504 Phone: 717-606-9882 |